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Tryptic digests of fragment &.,_~s of penicilloylated serum albumin, obtained from a penicillin-treated patient or pre- 
pared by in vitro conjugation, were analyzed by HPLC. Determinations of benzyl penicilloyl groups (BPQ) were per- 
formed on the different fractions. Three BPQ-containing peptides were identified by their amino acid sequence and the 
bound BPQ was located on lysines 190, 195 and 199 and serine 193. These four main BPO-binding sites are all located 
on a very short region (10 amino acid residues) of the albumin molecule at the junction of domains 1 and 2. 
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1. INTRODUCTION 
Benzyl penicilloyl groups (BPO) result from the 
cleavage of the ,&lactam ring of penicillin G. They 
form covalent binding between their carbonyl 
group and e-amino groups of albumin molecules. 
They thus give rise to penicilloyl-albumin con- 
jugates which have lost all antibacterial activity but 
possess an immunogenic potential; BP0 are thus 
considered to be the major antigenic determinant 
in penicillin allergy [l-3]. 
In patients treated with large amounts of 
penicillin, a transient bisalbuminemia was ob- 
served [4] and it has been demonstrated that the 
covalent fixation of BP0 was responsible for the 
presence of the fast electrophoretic band of 
albumin [5]. Recently BPO-binding sites have been 
located on the fragment Cr24...29s of albumin, on 
histidine 146 [6] or on lysine 199 [7]. Since then 
other fragments have been isolated and the pur- 
pose of this work was to complete this analysis and 
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identify the main BPO-binding sites located on the 
fragment C of albumin molecule which are in- 
volved in both in vivo and in vitro conjugation of 
BP0 with albumin. 
2. MATERIALS AND METHODS 
2.1. Reagents and penicitloylated albumins 
For high-performance liquid chromatography (HPLC), all 
the chemicals used were of HPLC grade, the water was filtered 
through an Elgastat UHQ system and the solvents were de- 
gassed before use. 
For amino acid analysis as for recurring Edman degradation, 
the chemicals used were of sequanal grade. 
The other reagents were of analytical grade. 
Serum was obtained from a patient in the Institut Pasteur 
Hospital, who had received intravenously 50 x lo6 IU penicillin 
G per day for 22 days. The collect was achieved 2 days after 
cessation of the treatment. The fast serum albumin was 
separated by ion-exchange chromatography on DEAE 
Sephadex and the elution performed with 0.2 M sodium 
phosphate buffer, pH 5.75, according to the methodology 
previously described [5] and slightly modified. 
A BPO-human serum albumin (BPO-HSA) conjugate was 
prepared in vitro by incubating 100 mg HSA (obtained from 
Centre National de Transfusion Sanguine), from which free fat- 
ty acids have been removed according to Chen [8], with 30 mg 
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benzyl penicillin (Specillin G, Specia) in 10 ml of 0.01 M 
phosphate buffer, pH 7.5, overnight at 37°C. Free penicillin 
was removed by ultrafiltration (micropartition system MPS-1, 
Amicon) and dialysis. The conjugate was then freeze dried. 
2.2. Analysis of the tryptic digests and separation of the 
penicilloylated peptides 
The preparation and purification of the two penicilloylated 
fragments C obtained by CNBr cleavage of patient’s serum fast 
albumin and of BPO-HSA conjugate; the tryptic digestion of 
these fragments and the reduction and carboxymethylation of 
the digests were performed as previously described [7]. 
The penicilloylated peptides were then isolated by 3 steps of 
HPLC using a Waters Ass. Chromatographic System. The first 
step, carried out on the whole tryptic digest after reduction and 
carboxymethylation, was performed on a Nucleosil 5-Cl8 col- 
umn (5 pm, 25 cm x 4.6 mm i.d.) (SociCtC Francaise Chromato 
Colonne) equilibrated with solvent AI (0.01 M phosphate buf- 
fer, pH 7). Elution was achieved by a 30 min linear gradient 
from 0 to 100% of solvent Br [solvent Ar/acetonitrile (40: 60, 
v/v)] at a flow rate of 1 ml/min. 
Fractions were collected every 0.2 min using a TDC 80 
microcol (Gilson). All the runs were performed at room 
temperature. Peptides were detected at 215 nm and BP0 was 
detected in the different fractions by enzyme immunoassay as 
previously described [7]. 
The BPO-containing fractions were then purified on a cation- 
exchange column (Polysulfoethyl Aspartamide, Poly LC) 
(5 Frn, 20 cm x 4.6 mm i.d.) equilibrated with solvent AZ 
[0.05 M phosphate buffer, pH 3/acetonitrile (50: 50, v/v)]. The 
elution system consists of a 5 min isocratic step with solvent AZ 
followed by a 40 min linear gradient from 0 to 100% of solvent 
Bz (solvent A2 + KC1 at a final concentration of 0.25 M). Frac- 
tions were collected and analyzed as before. 
A final third step of purification and desalting was operated 
on the BPO-containing fractions by using a Nucleosil5C18 col- 
umn equilibrated with solvent An (0.05% aqueous solution of 
trifluoroacetic acid (TFA)). Elution was achieved with a 30 min 
linear gradient of solvent B3 (acetonitrile/2-propanol/water 
(2: 1:2, v/v), 0.05% TFA) and the fractions were collected 
every 0.1 min. 
2.3. Identification of peptides and location of BPO-binding 
sites 
Sequencing was achieved using a 470A sequenator connected 
to a 12OA PTH HPLC analyzer (Applied Biosystems). 
A recurring Edman degradation using Tarr’s procedure [9] 
was performed on each peptide and the EIA of BP0 was realiz- 
ed at each cycle on the phenylthiohydantoin (PTH) derivative. 
3. RESULTS 
3.1. Obtainment of the penicilloylated peptides 
from tryptic digests of fragments C 
The HPLC patterns of the two tryptic digests of 
in vivo and in vitro penicilloylated albumin 
fragments C were identical. Fig.1 shows that ob- 
tained with the in vitro conjugate. In both cases 3 
BPO-containing peaks were collected e.g. Pep 12, 
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Pep 15 and Pep 16 at retention times (RT) of 12, 
15 and 16.7 min, respectively. 
Pep 12 and Pep 15 were isolated and analyzed in 
the second step of purification. Fig.2 shows this 
ion-exchange HPLC pattern. For each of these two 
peptides a single BPO-containing peak was ob- 
tained and collected at RT 6.2 and 14.2 min for 
Pep 12 and Pep 15, respectively, while numerous 
non-penicilloylated contaminating peptides were 
discarded. This second step of purification ap- 
peared to be unnecessary for Pep 16. 
In order to obtain a complete purification of the 
BP0 peptides and to prepare them free of salts for 
sequencing, a third step of purification was per- 
formed on the 3 peptides. Fig.3 shows the patterns 
of the reversed-phase HPLC using the TFA elution 
system. 
For the 3 steps of the purification procedure, 
identical profiles were obtained with the in vivo 
conjugate, the 3 purified BP0 peptides obtained at 
the different steps of the analytical procedure be- 
ing separated and collected at exactly the same 
retention times as those presented for the in vitro 
conjugate. 
In both cases, the proportion of the total BP0 
present in fragment C was -10% in Pep 12, 30% 
in Pep 15 and 40% in Pep 16. These 3 peptides thus 
account for -80% of the total BP0 present in the 
fragment C . 
3.2. Identification of peptides 
Each of the purified BP0 peptides prepared 
from the in vivo and in vitro penicilloylated 
albumins was analyzed for its amino acid se- 
quence. In both cases, the patterns were identical 
(e.g. separated at the same RT). 
Pep(s) 12: 
Asp-Giu- Gly - -Ala - Ser - Ser -Ala - Lys 
-- - ------ 
Pep(s) 15: 
Ala - Ser - Ser -Ala- - Gln -Arg 
-- - _L--- 
Pep(s) 16: 
Leu - - CMCys -Ala - Ser - Leu - Gln - Lys 
-- - ----- 
No amino acid could be identified in the fourth 
cyck of the sequencing of Pep(s) 12. This sequence 
corresponds to that of peptide 187-195 of the 
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Fig.1. Reversed-phase HPLC analysis (phosphate buffer/acetonitrile, pH 7) of the tryptic digests of the whole fragment Crz4-29s from 
penicilloylated albumin. Pep 12 (RT = 12 min), Pep 15 (RT = 15 min) and Pep 16 (RT = 16.7 min) were isolated for further 
purifications. (-) Peptide detection at 215 nm; (---) EIA determination of BP0 on the corresponding fractions. 
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Fig.2. Cation-exchange HPLC analysis (phosphate bufferjacetonitrile, pH 3) of fragments isolated in fig.1. (a) Pep 12, @) Pep 15. 
(1) Peptide detection at 215 nm; (---) EIA determination of BP0 on the corresponding fractions. 
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Fig.3. HPLC purification (TFA/acetonitrile/2-propanol/water) of fragments isolated in figs 1 and 2. (a) Pep 12, (b) Pep 15, (c) Pep 
16. (-) Peptide detection at 215 nm; (---) EIA determination of BP0 on the corresponding fractions. 
‘normal’ serum albumin [lo] suggesting that bin- 
ding of BP0 occurs at lysine 190. 
Concerning Pep(s) 15, the fifth cycle of the se- 
quencing corresponding to lysine 195 of peptide 
191-197 gave no PTH derivative and can be sup- 
posed to correspond to the BPO-binding site of 
this peptide. It should also be noticed that less 
PTH serine was measured in the third cycle than in 
the second one. This result is unexpected since a 
-lo- 15% overlap is usually observed and suggests 
that a part of Ser-193 could be undetected uring 
sequencing. 
Concerning Pep(s) 16 the sequencing pattern 
suggests it corresponds to segment 198-205, BP0 
being fixed on lysine 199. 
In order to confirm that the missing residue in 
the sequencing is the real BPO-binding site, BP0 
determinations were done again at each cycle of 
the Edman degradation of purified peptides 12, 15 
and 16. Concerning Pep 16, these determinations 
were performed on both peptides obtained from in 
vivo and in vitro penicilloylated albumins. For Pep 
12 and Pep 15, they were only performed on the in 
vitro conjugate since too small quantities of 
purified peptides remained available after the 
analysis of the in vivo penicilloylated albumins. 
3.2.1. Pep 16 
Most of the BP0 was detected in the second cy- 
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cle (Lys-199). Only traces corresponding to a 
-10% overlap were detected in the third cycle 
while no BP0 was detected in either the first and 
fourth cycle, or the residual tetrapeptide. 
3.2.2. Pep 12 
BP0 was detected in the fourth cycle (Lys-190) 
while a lo- 15% overlap was still present in the 
fifth step. No BP0 was present in any of the other 
cycles. 
3.2.3. Pep 15 
Most of the BP0 (-50% of the total BP0 pre- 
sent on this fragment) was detected in the fifth cy- 
cle (Lys-195) and a -10% overlap in the sixth 
cycle. However, a significant amount of BP0 
(-30%) was detected in the third cycle corre- 
sponding to Ser-193 which was partly missing in 
the sequencing pattern. A -10% BP0 overlap was 
still present in the fourth cycle. 
It has to be mentioned that the whole procedure 
was performed on a blank HSA sample and on 
blank lysine and serine phenylthiohydantoin 
derivatives. No false positive result occurs at any 
step of the analysis. 
4. DISCUSSION . 
The location of BPO-binding sites on fragment 
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C of HSA is supported by the identification of 
penicilloylated lysines 190, 195 and 199. The 
absence of cleavage of the bonds 190-191, 
195-196 and 199-200 in the peptides 12, 15 and 16 
confirms that the lysine is substituted. 
It is worth noticing that the same binding sites 
have been identified for both in vitro and in vivo 
serum albumin penicilloylation; they account for 
-80010 of the total BP0 present on the albumin 
fragment C. 
Lysine 199 (on Pep 16: 198-205), already iden- 
tified as a binding site for in vivo fixation of BP0 
to albumin [7], is confirmed and appears to’be in- 
volved in in vitro conjugation too. 
We did not find any BP0 on histidine 146 either 
on the in vivo or on the in vitro penicilloylated 
albumins. This residue was described as a BPO- 
binding site by Lafaye and Lapresles [6] working 
on penicilloylated albumin isolated and analyzed 
from a pool of penicillin-treated patients’ sera by 
a methodology slightly different from ours. 
Although no definite and unequivocal identifica- 
tion of a penicilloylated histidine-146 was brought, 
this binding site could exist and account for a part 
of the non-identified bound BP0 (-20%) in our 
study. However, one should notice that this lone 
putative histidine BPO-binding site cannot by itself 
explain the faster mobility of the penicilloylated 
albumin from which it has been isolated, since at 
pH 8.7 (at which the electrophoretic separation of 
the penicilloylated fast albumin is observed [5]), 
the histidine residues (p& = 7) are not protonated 
and an eventual fixation of BP0 would not have 
changed the global electric charge of the albumin 
molecule. 
On the opposite the fixation of BP0 on various 
lysine residues, as previously hypothesized [l-4], 
can explain the faster mobility and the heterogenei- 
ty observed on penicilloylated albumins [5]. 
Moreover one must notice the respective posi- 
tions of the reactive lysine and serine residues in 
the sequence of serum albumin. Each lysine is 
located near a serine from which it is separated by 
two amino acids e.g. 
Pep 12: - - - Lysnl0- - Serr93 
Pep 15: Serl92 - - Lys195- - - 
Pep 16: - - - LYS199- - Ser202 
These sequences represent he configuration in 
which a-helix Lys and Ser residues are the nearest. 
This supports the mechanism proposed by Yamana 
et al. [I I] for the formation of penicilloylamide 
allergenic determinants. The penicilloylation of a 
hydroxyl group (e.g. of a serine residue) should oc- 
cur rapidly with the assistance of general acid-base 
catalysis toward penicillin ,&lactam to yield the 
corresponding penicilloyl esters, which are then 
rapidly converted to a stable penicilloylamide by 
nucleophilic attack by a proximate e-amino group 
of lysine on the protein. What is needed is the com- 
bination of closely located functional groups on 
the protein. 
This proposed mechanism is confirmed by the 
presence of the penicilloylated serine residue 193 
on Pep 12. However Serr03 and Lysi90 are never 
both penicilloylated on the same molecule; Ser103 
could thus be considered as a first intermediate site 
which rapidly reacts with penicillin before the BP0 
is transferred to the proximate Lysi00. 
According to the structural protein model of 
Brown [lo] all the BPO-binding sites identified 
here are located on a very short fragment of the 
albumin molecule (10 amino acids residues: 
190-200) located at the junction of domains 1 and 
2. This fragment is part of a larger flexible region 
of human serum albumin possessing high-affinity 
binding sites for salicylate, glucose, warfarin and 
other ligands [12-151. 
Concerning the binding of BP0 to HSA the 
same reactive sites are involved whether the 
penicilloylation occurs in vivo in the penicillin- 
treated patient or in vitro under ‘physiological’ 
conditions. 
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